EGFR and non-small cell lung carcinoma: As shown in Supplementary Figure 2, the results indicated that the IC50 values of EGFR tyrosine kinase inhibitors gefitinib, erlotinib, and cisplatin in EMT Cluster 1 were significantly higher lower than EMT Cluster 2 (p < 0.0001), revealing that NSCLC patients in EMT Cluster one received better clinical responses to tyrosine kinase inhibitors or chemotherapy.